



PPL Standard Condition 18 Notification Form

Please use this form to notify the Animals in Science Regulation Unit (ASRU) of procedural-related adverse effects that have exceeded or are likely to exceed the severity limitations or controls described in the project licence. ASRU will use this information to determine whether any further action is required.

Do not use to report:

- adverse effects that are due to non-procedural issues;
- potential non-compliance (report by other means);
- issues without adverse welfare consequences.

If you are in doubt whether or not you need to fill in this form, please contact your assigned Inspector.

Please clearly title your document: '**ASRU_establishment name_PPL number_PPLh surname_date_sc18**' and send to your Inspector (e.g. using cjsm) with the subject heading 'PPL SC 18 Notification PPL [Number]

Establishment Licence name	University of Cambridge
Establishment Licence number	X81BD37B1
Name of PPL holder	Professor Ziad Mallat
PPL number	PP9485757
Protocol no	4
Protocol title	breeding and maintenance
Severity classification	Mild

1. Date of incident	14/03/2022
2. Species	Mouse
3. Brief details of study and how the limits or constraints have been breached	The female mouse (IL-33KO) looked to be in pain, showing the grimace scale and being unable to bare weight on her front paws. She had a scabby tail and flaky feet. D.O.B 15/9/21
4. Have you taken advice from the Named Animal Care and Welfare Officer/Named Veterinary Surgeon/others?	Yes, it has been suggested that this breeding pair should be separated, to avoid any further pups being born with this phenotype.
5. Cause of Problem, if known	Not known. This problem has never been encountered before despite having this strain since 2018. A histology report was requested. According to the histology report, the feet and tail were markedly affected by inflammation, surprisingly with few bacteria seen; possibly there was irritation /damage from the bedding. Some foci of similar inflammation were found in other organs and are probably likely related to sepsis spread of the inflammation. See histopathology report, attached.
6. Action that has been or will be taken <i>(For example, formulation of drug changed, supportive treatment given, study design modified). If no action needed, indicate why (for example, none required as study has been terminated and will not be repeated)</i>	Female breeder culled. Histopathology test done.
7. Reported by (name)	Yuning Lu
8. Date	24/03/2022

*****For official use*****

Inspector's comments and recommendations:

Comments and recommendations	
Inspector name	
Date	

CONFIDENTIAL